Compare Amphastar Pharmaceuticals Inc (AMPH) vs SYSCO Corporation (SYY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs SYSCO Corporation — how do they compare? Amphastar Pharmaceuticals Inc trades at $19.38 (market cap $826.08M), while SYSCO Corporation trades at $84.21 (market cap $40.09B). The key difference: SYSCO Corporation is far larger — about 48.5× Amphastar Pharmaceuticals Inc's market cap, and SYSCO Corporation pays a 2.62% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | SYY | |
|---|---|---|
Market Cap | $826.08M | $40.09B |
Sector | Health | Consumer Staples |
52-Week High | $30.81 | $91.16 |
52-Week Low | $16.87 | $69.30 |
Enterprise Value | $1.22B | $53.57B |
Dividend Yield | — | 2.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
SYY trades at $83.83, up 2.19% today, near the consensus price target of $83.67. The stock shows bullish technical signals with strong moving averages and support at $81. Recent earnings beat expectations in Q3 and Q4 2025, though Q1 2026 missed slightly. Revenue grew to $81.37B in 2025, with net income of $1.83B. The company maintains a dividend with the next payment scheduled for July 2026.
Outlook remains positive with 60% analyst buy ratings and a high target of $86. Risks include margin pressure from rising costs and competitive threats. The transformative Restaurant Depot acquisition could drive long-term growth, but investors should monitor execution and macroeconomic impacts on food distribution demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About SYSCO Corporation
Sysco is the largest U.S. food-service distributor, boasting 17% market share of the highly fragmented food-service distribution industry. Sysco distributes over 400,000 food and nonfood products to restaurants (63% of revenue), healthcare facilities (8%), education and government buildings (8%), travel and leisure (7%), and other locations (14%) where individuals consume away-from-home meals. In fiscal 2022, 82% of the firm's revenue was U.S.-based, with 7% from Canada, 4% from the U.K., 2% from France, and 4% other.
Read more on SYY →
